CorMedix Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

CorMedix wird ein Gewinn- und Umsatzwachstum von 63.9% bzw. 49.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 64.6% pro Jahr wachsen soll.

Wichtige Informationen

63.9%

Wachstumsrate der Gewinne

64.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	49.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

Apr 06

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Nov 02

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 31

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Feb 25

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

Aug 08

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 16

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Mar 01

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Sep 09

CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price

Feb 11

We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely

Jan 04

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:CRMD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	162	82	N/A	N/A	2
12/31/2025	82	-1	-11	-11	4
12/31/2024	25	-42	-47	-47	4
3/31/2024	N/A	-50	-46	-45	N/A
12/31/2023	N/A	-46	-39	-38	N/A
9/30/2023	0	-40	-34	-34	N/A
6/30/2023	0	-37	-31	-31	N/A
3/31/2023	0	-33	-28	-28	N/A
12/31/2022	0	-30	-25	-24	N/A
9/30/2022	0	-29	-25	-24	N/A
6/30/2022	0	-31	-25	-24	N/A
3/31/2022	0	-28	-23	-21	N/A
12/31/2021	0	-28	-23	-21	N/A
9/30/2021	0	-27	-22	-21	N/A
6/30/2021	0	-25	-23	-23	N/A
3/31/2021	0	-24	-21	-21	N/A
12/31/2020	0	-22	-22	-22	N/A
9/30/2020	0	-21	-20	-20	N/A
6/30/2020	0	-47	-17	-17	N/A
3/31/2020	0	-44	-16	-16	N/A
12/31/2019	0	-44	-15	-15	N/A
9/30/2019	0	-36	-18	-18	N/A
6/30/2019	1	-14	-20	-20	N/A
3/31/2019	1	-22	-24	-24	N/A
12/31/2018	0	-27	-24	-24	N/A
9/30/2018	0	-39	-24	-24	N/A
6/30/2018	0	-39	-26	-25	N/A
3/31/2018	0	-36	-29	-29	N/A
12/31/2017	0	-33	N/A	-29	N/A
9/30/2017	0	-29	N/A	-28	N/A
6/30/2017	0	-28	N/A	-28	N/A
3/31/2017	0	-28	N/A	-24	N/A
12/31/2016	0	-25	N/A	-22	N/A
9/30/2016	0	-22	N/A	-19	N/A
6/30/2016	0	-18	N/A	-16	N/A
3/31/2016	0	-17	N/A	-16	N/A
12/31/2015	0	-18	N/A	-13	N/A
9/30/2015	0	-17	N/A	-10	N/A
6/30/2015	0	-17	N/A	-9	N/A
3/31/2015	0	-9	N/A	-7	N/A
12/31/2014	0	-21	N/A	-6	N/A
9/30/2014	0	-22	N/A	-6	N/A
6/30/2014	0	-19	N/A	-5	N/A
3/31/2014	0	-25	N/A	-4	N/A
12/31/2013	0	-10	N/A	-4	N/A
9/30/2013	N/A	-7	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CRMD wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: CRMD wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: CRMD wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: CRMDDie Einnahmen des Unternehmens (49.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: CRMDDie Einnahmen des Unternehmens (49.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CRMD in 3 Jahren voraussichtlich hoch sein wird

CorMedix Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven date moved forward to 2025

Price target decreased by 7.0% to US$13.25

Forecast to breakeven in 2026

Price target decreased by 18% to US$13.75

Price target increased to US$15.00

Price target increased to US$15.00

Recent updates

CorMedix Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

CorMedix Inc. to Report Q1, 2024 Results on May 09, 2024

CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)

New minor risk - Share price stability

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

CEO & Director recently bought US$51k worth of stock

Forecast breakeven date moved forward to 2025

CorMedix Inc. to Report Q4, 2023 Results on Mar 12, 2024

Price target decreased by 7.0% to US$13.25

CorMedix Inc. Updates Related to Its Business and Anticipated Launch of DefenCath

Cormedix Inc. Announces Commercial and Operational Updates

Forecast to breakeven in 2026

CorMedix Inc. Approves the Separation of Employment of Phoebe Mounts

CorMedix Inc. Announces the Appointment of Beth Zelnick Kaufman, Esq. as Executive Vice President, Chief Legal Officer, and Corporate Secretary, Effective December 12, 2023

CorMedix Inc. Announces FDA Approval of DefenCath(R) to Reduce the Incidence of Catheter Related Bloodstream Infections in Adult Hemodialysis Patients

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.17 loss in 3Q 2022)

CorMedix Inc. to Report Q3, 2023 Results on Nov 14, 2023

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

CorMedix Inc., Annual General Meeting, Oct 26, 2023

Cormedix Inc. Announces Resignation of Paulo F. Costa as Member of the Board of Directors, Effective as of October 15, 2023

Price target decreased by 18% to US$13.75

First half 2023 earnings released: US$0.49 loss per share (vs US$0.38 loss in 1H 2022)

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix Inc. to Report Q2, 2023 Results on Aug 08, 2023

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

Cormedix Inc. Announces Resubmission of New Drug Application for Defencath

First quarter 2023 earnings released: US$0.24 loss per share (vs US$0.18 loss in 1Q 2022)

CorMedix Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Cormedix Inc. Announces Promotions in Commercial and Tech Ops

CEO & Director recently bought US$76k worth of stock

Price target increased to US$15.00

High number of new and inexperienced directors

Price target increased to US$15.00

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.23 loss in 3Q 2021)

CorMedix Inc. to Report Q3, 2022 Results on Nov 10, 2022

CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference

CorMedix Inc., Annual General Meeting, Oct 13, 2022

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.12 loss in 2Q 2021)

Consensus forecasts updated

CorMedix Inc. Announces Regulatory and Manufacturing Updates

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

CorMedix Inc. to Report Q2, 2022 Results on Aug 11, 2022

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix Inc.(NasdaqGM:CRMD) dropped from Russell 2000 Dynamic Index

High number of new and inexperienced directors

Consensus forecasts updated

No longer forecast to breakeven

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

CorMedix Inc. Announces Executive Changes

CorMedix Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Price target decreased to US$22.00

No longer forecast to breakeven

CorMedix Inc. Announces Formation of New Scientific Advisory Board

Consensus forecasts updated

No longer forecast to breakeven

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

Cormedix Inc. Resubmits the New Drug Application for DefenCath to Address the Complete Response Letter Issued by the U.S. Food and Drug Administration

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Independent Chairman of the Board recently bought US$51k worth of stock

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.22 loss in 3Q 2020)

Price target decreased to US$22.00

CEO & Director Khoso Baluch has left the company

Executive Vice President for Technical Operations John Armstrong has left the company

Pomerantz Law Firm Announces the Filing of A Class Action Against CorMedix Inc. and Certain Officers

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Price target increased to US$26.00